This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.
Pfizer (PFE) Q2 Earnings Beat, View Up on COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It lifts its guidance for 2021.
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 2.66% and 4.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Comcast, Coca-Cola, Bristol-Myers Squibb, Cisco Systems and Stryker
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Coca-Cola, Bristol-Myers Squibb, Cisco Systems and Stryker
Top Analyst Reports for Comcast, Coca-Cola & Bristol-Myers Squibb
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), The Coca-Cola Company (KO), and Bristol-Myers Squibb (BMY).
Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY
by Zacks Equity Research
Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.
Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $68.34 in the latest trading session, marking a +0.56% move from the prior day.
Will Pfizer (PFE) Beat Expectations This Earnings Season?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the second quarter.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $67.96, moving +1.19% from the previous trading session.
Healthcare ETFs in Focus as Q2 Earnings Unfold
by Sweta Killa
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX
by Zacks Equity Research
The biotech sector was in focus last week on updates form Regeneron (REGN) and Bristol Myers (BMY).
Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.
Company News for Jul 19, 2021
by Zacks Equity Research
Companies in The News Are: KSU,ALV,VLRS,BMY
Bristol Myers Squibb (BMY) Stock Moves -0.19%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $67.30, moving -0.19% from the previous trading session.
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $67.43, marking a -0.66% move from the previous day.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $67.16, moving +0.7% from the previous trading session.
Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H
by Zacks Equity Research
Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.
Bristol Myers Squibb (BMY) Stock Moves -0.67%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $66.69 in the latest trading session, marking a -0.67% move from the prior day.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $66.95, marking a +0.59% move from the previous day.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $66.56 in the latest trading session, marking a -0.39% move from the prior day.
Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.
Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy
by Zacks Equity Research
Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.